FDA Approves First Interchangeable Biosimilar Insulin product for Diabetes treatment Hina Zahid29 July 2021 11:45 AM GMTU.S. Food and Drug Administration has approved first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and...
Low- dose Pioglitazone improves NAFLD in type 2 diabetes: Study Dr. Shravani Dali29 July 2021 4:00 AM GMTComplete 1-year treatment with low- dosage pioglitazone shows significant improvement in non-alcoholic fatty liver disease independent of glycaemic...
Telmisartan use reduces risk of dementia in hypertensive patients with Type 2- DM: Study Dr. Shravani Dali28 July 2021 6:15 AM GMTAdministering Telmisartan in type-2 diabetes patients with hypertension is linked with reduced risk of dementia and ischemic stroke, suggests a...
Impaired blood sugar levels in Type-2 diabetes tied to Poor Cardiac function: Study Dr. Shravani Dali24 July 2021 6:15 AM GMTThe cardiac function gets impaired in patients with type-2 diabetes, who have poor blood sugar control, suggests a study published in the Diabetes Re...
Intraglomerular dysfunction may predict kidney failure in type 2 diabetes patients: Study Medha20 July 2021 3:30 AM GMTUSA: Intraglomerular dysfunction can predict kidney failure in type 2 diabetes (T2D) patients, suggests a recent study in Diabetes, the journal of the ...
Diabetes: Study suggests SGLT2 inhibitors role in primary prevention of diabetic kidney disease Medha19 July 2021 5:18 AM GMTDelhi: Dapagliflozin, an SGLT2 inhibitor, may be used for the primary prevention of diabetic kidney disease, suggests recent results from DECLARE-TIMI ...
Liraglutide addition to SGLT2 inhibitors intensifies type 2 diabetes treatment: Study Medha17 July 2021 7:15 AM GMTDelhi: Liraglutide (1.8 mg) seems to be an effective way to intensify the treatment of type 2 diabetes irrespective of BMI, HbA1c, insulin resistance, ...
SGLT-2 Inhibitors Increase Retinal Vein Occlusion Risk in Diabetics, Study Finds MD Bureau16 July 2021 3:30 AM GMTSGLT2 inhibitors are associated with an increased risk of RVO when compared with other glucose lowering drugs.
Sotagliflozin use linked to reduced risk of heart attack, heart failure and stroke in diabetics: Study Medha15 July 2021 3:30 AM GMTSotagliflozin is not FDA approved and if it is brought to the market, it would signify a major advance in the care of patients with diabetes, especiall...
Tirzepatide provides significant blood sugar and weight reduction in diabetics: SURPASS Trial Hina Zahid14 July 2021 6:15 AM GMTTirzepatide is delivering unprecedented results that could help millions of people with type 2 diabetes and their health care providers reach A1C and w...
Liraglutide and insulin most effective in maintaining optimal blood sugar levels in diabetics: Study Medha13 July 2021 5:30 AM GMTResults of GRADE demonstrated that liraglutide and insulin were the most effective of the four medications in keeping A1C levels less than 7%. USA...
Dulaglutide lowers erectile dysfunction risk in men with type 2 diabetes: Lancet Medha12 July 2021 5:45 AM GMTCanada: The long-term use of dulaglutide, a GLP-1 receptor agonist, may reduce the risk of severe erectile dysfunction in men with type 2 diabetes,...
